$INO The announcements that FDA clears INO to begin mid-stage testing of its Covid-19 vaccine candidate (INO-4800), and INO disclosed the phase2/3 trail will be funded by The company also disclosed the phase-II/III trial will be funded by the DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense in coordination with the Office of the Assistant Secretary of Defense for Health Affairs and the Defense Health Agency. The amount of the funding was not disclosed. The downward swing for INO is not surprising. Bears have been advocating sell, sell, sell. Perhaps, the most likely reason is just that - some investors are taking profits off the table after INO's announcement. Keep in mind, the biotech's prospects remain optimistic - at least for all INO's investors. News on FDA's decision on p3 partial hold, peer review - perhaps additional funding are still up in the air. Down we go for now, so don on your parachute! Reference: expresspharma.in/covid19-up...
  • 8